Michele Cleary joined The Mark Foundation for Cancer Research as Chief Executive Officer in January 2017. Prior to that, she was Vice President at Bristol-Myers Squibb (BMS). At BMS, she led early clinical and translational research teams using cutting-edge technologies to accelerate drug discovery and development for cancer and other diseases. Before joining BMS, Michele held several senior level positions at Merck & Co., Inc., overseeing the development and application of innovative platforms for understanding molecular mechanisms of cancer, identification of new therapeutic approaches for multiple diseases, and functional validation of novel drug targets identified through human genetics. At Merck, her research teams also conducted pioneering work on microRNAs as therapeutic targets and biomarkers in cancer.
Michele is co-author of more than 50 primary research papers in the fields of drug target biology, RNA interference, microRNAs, cell cycle, biomarkers, genomics and oncology. She is also co-inventor on multiple patents for new technologies with direct application to cancer drug development. Michele received a PhD in Molecular Microbiology and Genetics from Stony Brook University and completed graduate research at Cold Spring Harbor Laboratory followed by postdoctoral training at Princeton University.